Clinical Trials Logo

Malignant Rhabdoid Tumors (MRT) clinical trials

View clinical trials related to Malignant Rhabdoid Tumors (MRT).

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT01747876 Terminated - Neuroblastoma Clinical Trials

Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma

Start date: May 28, 2013
Phase: Phase 1
Study type: Interventional

LEE011 is a small molecule inhibitor of CDK4/6. LEE011 has demonstrated in vitro and in vivo activity in both tumor models. The primary purpose of this study was to determine the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) in pediatric patients and to delineate a clinical dose to be used in future studies. This study was also to have assessed the safety, tolerability, PK and preliminary evidence of antitumor activity of LEE011 in patients with MRT or neuroblastoma.